Technical Analysis for CALA - Calithera Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Historical CALA trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Spinning Top | Other | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Oversold Stochastic | Weakness | -2.27% | |
Oversold Stochastic | Weakness | -1.83% | |
New 52 Week Closing Low | Bearish | -0.92% | |
New 52 Week Low | Weakness | -0.92% | |
Wide Bands | Range Expansion | -0.92% | |
Down 3 Days in a Row | Weakness | -0.92% | |
Lower Bollinger Band Touch | Weakness | -0.92% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
60 Minute Opening Range Breakout | 1 day ago |
Down 3% | 1 day ago |
Down 2 % | 1 day ago |
Down 1% | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/16/2021
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Solid Tumors Treatment Of Cancer Oncology Lymphoma Hematology Tumor Metabolism Multiple Myeloma Targeted Therapy Anatomical Pathology Phosphoinositide 3 Kinase Inhibitor Leukemias Glutaminase
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Solid Tumors Treatment Of Cancer Oncology Lymphoma Hematology Tumor Metabolism Multiple Myeloma Targeted Therapy Anatomical Pathology Phosphoinositide 3 Kinase Inhibitor Leukemias Glutaminase
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.42 |
52 Week Low | 2.08 |
Average Volume | 992,437 |
200-Day Moving Average | 3.81 |
50-Day Moving Average | 2.75 |
20-Day Moving Average | 2.42 |
10-Day Moving Average | 2.31 |
Average True Range | 0.14 |
ADX | 48.69 |
+DI | 6.84 |
-DI | 31.50 |
Chandelier Exit (Long, 3 ATRs ) | 2.53 |
Chandelier Exit (Short, 3 ATRs ) | 2.49 |
Upper Bollinger Band | 2.75 |
Lower Bollinger Band | 2.09 |
Percent B (%b) | 0.09 |
BandWidth | 27.25 |
MACD Line | -0.17 |
MACD Signal Line | -0.15 |
MACD Histogram | -0.0132 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.26 | ||||
Resistance 3 (R3) | 2.27 | 2.23 | 2.24 | ||
Resistance 2 (R2) | 2.23 | 2.20 | 2.23 | 2.24 | |
Resistance 1 (R1) | 2.19 | 2.18 | 2.17 | 2.19 | 2.23 |
Pivot Point | 2.16 | 2.16 | 2.15 | 2.15 | 2.16 |
Support 1 (S1) | 2.12 | 2.13 | 2.10 | 2.11 | 2.07 |
Support 2 (S2) | 2.08 | 2.11 | 2.08 | 2.06 | |
Support 3 (S3) | 2.04 | 2.08 | 2.06 | ||
Support 4 (S4) | 2.04 |